logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Sacituzumab govitecan for metastatic or unresectable locally advanced triple-negative breast cancer – third line

< Back

Sacituzumab govitecan for metastatic or unresectable locally advanced triple-negative breast cancer – third line

Drugs

Cancer and Palliative Care

January 2021


Sacituzumab govitecan is in clinical development for the treatment of adult patients with metastatic or unresectable locally advanced triple-negative breast cancer (TNBC) who have received at least two prior therapies. TNBC patients tend to have worse clinical outcomes than non-TNBS groups due to its high-risk biological characteristics and lack of effective treatments.
Sacituzumab, a type of molecule called a monoclonal antibody, targets the Trop-2 protein; which is found in more than 90% of TNBCs. Sacituzumab govitecan is an antibody-drug conjugate. The linking compound attaches (conjugates) the monoclonal antibody sacituzumab to the SN-38 chemotherapy. Sacituzumab govitecan is administered as an intravenous infusion. If licensed, sacituzumab govitecan will offer an additional treatment option for adult patients with metastatic or unresectable locally advanced TNBC who have received at least two prior therapies.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts